<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antifungals, Triazole: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i300.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i300.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i300.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i288.htm">Antifungals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i299.htm" title="Previous: Miconazole">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1060.htm" title="Next: Posaconazole">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i300">Antifungals, Triazole</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antifungals, Triazole</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i290.htm" name="_290">Amphotericin</a></td><td> triazoles possibly antagonise effects of amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  triazoles given with atorvastatin </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  triazoles given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm" name="_95">Fentanyl</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of fentanyl </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  triazoles given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td class="cBV"><b>avoidance of  triazoles advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i200.htm" name="_200">Rifabutin</a></td><td class="cBV"><b> triazoles possibly increase plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td> triazoles possibly increase plasma concentration of saquinavir </td><td></td></tr></tbody></table><p>Antifungals, Triazole belongs to <b>Antifungals</b>
          but <b>Antifungals</b>
          has no interactions information.
        </p><p><b>Posaconazole</b> belongs to
      <b>Antifungals, Triazole</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


























<tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  posaconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> posaconazole increases plasma concentration of atazanavir </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  posaconazole given with atorvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly reduced by carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> posaconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by cimetidine </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  posaconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by efavirenz </b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> posaconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i272.htm">Glipizide</a></td><td> posaconazole possibly enhances hypoglycaemic effect of glipizide </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>manufacturer of  posaconazole advises avoid concomitant use with histamine H<sub>2</sub>-antagonists (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  posaconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> posaconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>manufacturer of  posaconazole advises avoid concomitant use with proton pump inhibitors (plasma concentration of posaconazole possibly reduced)</td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> posaconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> posaconazole increases plasma concentration of rifabutin (also plasma concentration of posaconazole reduced)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  posaconazole reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  posaconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  posaconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td> posaconazole possibly increases plasma concentration of sirolimus </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> posaconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  posaconazole possibly increased by telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1002.htm">Vinblastine</a></td><td class="cBV"><b> posaconazole possibly inhibits metabolism of vinblastine (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i815.htm">Vincristine</a></td><td class="cBV"><b> posaconazole possibly inhibits metabolism of vincristine (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table><p><b>Voriconazole</b> belongs to
      <b>Antifungals, Triazole</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td class="cBV"><b> voriconazole increases plasma concentration of alfentanil (consider reducing dose of alfentanil)</b></td><td></td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  voriconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> voriconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> voriconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> voriconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of diazepam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td> voriconazole increases plasma concentration of diclofenac </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by efavirenz , also plasma concentration of efavirenz increased (increase voriconazole dose and reduce efavirenz dose)</b></td><td></td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td> voriconazole possibly increases plasma concentration of esomeprazole </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td> voriconazole increases plasma concentration of ibuprofen </td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of methadone (consider reducing dose of methadone)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> voriconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  voriconazole increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td> voriconazole increases plasma concentration of omeprazole (consider reducing dose of omeprazole)</td><td></td></tr><tr><td><a href="41001i901.htm">Oxycodone</a></td><td class="cBV"><b> voriconazole increases plasma concentration of oxycodone </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  voriconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly reduced by phenobarbital—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of phenytoin , also phenytoin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for phenytoin toxicity)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  voriconazole possibly increased by progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> voriconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> voriconazole increases plasma concentration of rifabutin , also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  voriconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td>possible increased risk of myopathy when  voriconazole given with simvastatin </td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  voriconazole reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> voriconazole possibly increases plasma concentration of sulfonylureas </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> voriconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  voriconazole possibly affected by telaprevir (possible increased risk of ventricular arrhythmias)</b></td><td></td></tr></tbody></table><p><b>Fluconazole</b> belongs to
      <b>Antifungals, Triazole</b>
          and has the following interaction information:
        </p><div>In general, fluconazole interactions relate to multiple-dose treatment</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





























<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> fluconazole inhibits metabolism of alfentanil (risk of prolonged or delayed respiratory depression)</td><td></td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td> fluconazole possibly increases plasma concentration of amitriptyline </td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> fluconazole possibly increases plasma concentration of bosentan—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td> fluconazole possibly increases plasma concentration of carbamazepine </td><td></td></tr><tr><td><a href="41001i898.htm">Celecoxib</a></td><td> fluconazole increases plasma concentration of celecoxib (halve dose of celecoxib)</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> fluconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fluconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td class="cBV"><b> fluconazole increases plasma concentration of diazepam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> fluconazole increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i69.htm">Flurbiprofen</a></td><td> fluconazole increases plasma concentration of flurbiprofen </td><td></td></tr><tr><td><a href="41001i603.htm">Fluvastatin</a></td><td> fluconazole increases plasma concentration of fluvastatin </td><td></td></tr><tr><td><a href="41001i530.htm">Hydrochlorothiazide</a></td><td>plasma concentration of  fluconazole increased by hydrochlorothiazide </td><td></td></tr><tr><td><a href="41001i783.htm">Ibuprofen</a></td><td> fluconazole increases plasma concentration of ibuprofen </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td> fluconazole increases plasma concentration of ivabradine—reduce initial dose of ivabradine</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> fluconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i920.htm">Nateglinide</a></td><td> fluconazole possibly enhances hypoglycaemic effect of nateglinide </td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b> fluconazole increases plasma concentration of nevirapine </b></td><td></td></tr><tr><td><a href="41001i961.htm">Parecoxib</a></td><td> fluconazole increases plasma concentration of parecoxib (reduce dose of parecoxib)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluconazole increases plasma concentration of phenytoin (consider reducing dose of phenytoin)</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> fluconazole increases plasma concentration of rifabutin (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  fluconazole accelerated by rifampicin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td> fluconazole increases plasma concentration of ritonavir </td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  fluconazole given with simvastatin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> fluconazole increases plasma concentration of sulfonylureas </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> fluconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> fluconazole possibly increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td> fluconazole increases plasma concentration of tipranavir </td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td class="cBV"><b> fluconazole increases plasma concentration of zidovudine (increased risk of toxicity)</b></td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Itraconazole</b> belongs to
      <b>Antifungals, Triazole</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





































































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> itraconazole possibly inhibits metabolism of alfentanil </td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td class="cBV"><b> itraconazole increases plasma concentration of aliskiren—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i406.htm">Alprazolam</a></td><td> itraconazole increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  itraconazole reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td>avoidance of  itraconazole advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  itraconazole given with atorvastatin </b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td> itraconazole possibly increases plasma concentration of bosentan </td><td></td></tr><tr><td><a href="41001i496.htm">Budesonide</a></td><td> itraconazole increases plasma concentration of <i>inhaled</i> budesonide </td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> itraconazole increases plasma concentration of buspirone (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i993.htm">Busulfan</a></td><td> itraconazole inhibits metabolism of busulfan (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>negative inotropic effect possibly increased when  itraconazole given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i469.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td> itraconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  itraconazole possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> itraconazole inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of  itraconazole increased by clarithromycin </td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> itraconazole possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> itraconazole possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> itraconazole possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> itraconazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i502.htm">Cyclophosphamide</a></td><td> itraconazole possibly increases side-effects of cyclophosphamide </td><td></td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td>avoidance of  itraconazole advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> itraconazole increases plasma concentration of digoxin </b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>manufacturer of  itraconazole advises avoid concomitant use with disopyramide </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  itraconazole reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> itraconazole increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> itraconazole increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i471.htm">Felodipine</a></td><td class="cBV"><b> itraconazole inhibits metabolism of felodipine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  itraconazole given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>plasma concentration of both drugs may increase when  itraconazole given with fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td> itraconazole increases plasma concentration of gefitinib </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> itraconazole possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  itraconazole reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> itraconazole increases plasma concentration of indinavir (consider reducing dose of indinavir)</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  itraconazole advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> itraconazole possibly inhibits metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i1125.htm">Micafungin</a></td><td>plasma concentration of  itraconazole increased by micafungin (consider reducing dose of itraconazole)</td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> itraconazole increases plasma concentration of midazolam (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> itraconazole inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  itraconazole possibly reduced by nevirapine—consider increasing dose of itraconazole</td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  itraconazole advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  itraconazole possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by phenytoin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  itraconazole reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> itraconazole possibly enhances hypoglycaemic effect of repaglinide </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by rifabutin—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  itraconazole reduced by rifampicin—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>combination of  itraconazole with ritonavir may increase plasma concentration of either drug (or both)</b></td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td>avoidance of  itraconazole advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> itraconazole increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  itraconazole given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> itraconazole increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1020.htm">Solifenacin</a></td><td> itraconazole increases plasma concentration of solifenacin </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> itraconazole increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> itraconazole possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td>plasma concentration of  itraconazole possibly increased by telaprevir </td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  itraconazole advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i815.htm">Vincristine</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of vincristine (increased risk of neurotoxicity)</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> itraconazole possibly increases plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1085.htm">Vinorelbine</a></td><td class="cBV"><b> itraconazole possibly inhibits metabolism of vinorelbine (increased risk of neurotoxicity)</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1060.htm" title="Posaconazole">Posaconazole</a></li><li><a href="41001i948.htm" title="Voriconazole">Voriconazole</a></li><li><a href="41001i301.htm" title="Fluconazole">Fluconazole</a></li><li><a href="41001i302.htm" title="Itraconazole">Itraconazole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i299.htm">Previous: Miconazole</a> | <a class="top" href="41001i300.htm#">Top</a> | <a accesskey="]" href="41001i1060.htm">Next: Posaconazole</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>